

**a**  $IC_{50}$  ( $\mu M$ )  
0.64  
> 10

Cell viability (Fraction of Control)

Nilotinib ( $\mu M$ )

ImR  
ImR+NiR

K562

**b**

Parental ImR+NiR Parental ImR+NiR

p-ABL

BCR/ABL

p-STAT5

STAT5

$\beta$ -Actin

K562 KU812

**c**

Parental ImR+NiR Parental ImR+NiR

FTO

METTL3

ALKBH5

$\beta$ -Actin

K562 KU812

**d**

Parental ImR+NiR Parental ImR+NiR

$m^6A$

Loading control

K562 KU812

**e**

Parental ImR+NiR

K562

$m^6A$  IP (Fold enrichment)

MERTK BCL-2

Parental ImR+NiR

KU812

$m^6A$  IP (Fold enrichment)

MERTK BCL-2

**f**

Parental ImR+NiR

K562

mRNA expression (Fold of change)

MERTK BCL-2

Parental ImR+NiR

KU812

mRNA expression (Fold of change)

MERTK BCL-2

**g**

Control Rhein

K562 ImR+NiR

mRNA expression (Fold of change)

MERTK BCL-2

Control Rhein

KU812 ImR+NiR

mRNA expression (Fold of change)

MERTK BCL-2

1

**f,g** qPCR of parental vs ImR+NiR cells (**f**) or ImR+NiR cells treated with 25  $\mu$ M rhein for 48 hours (**g**).

In **b-g**, data represent three independent experiments.